Skip to main content

DermacinRx ​ FoliPlus D Disease Interactions

There are 6 disease interactions with DermacinRx ​ FoliPlus D (cholecalciferol / folic acid).

Major

Folic acid (applies to DermacinRx ​ FoliPlus D) anemia

Major Potential Hazard, High plausibility. Applicable conditions: Anemia of Unspecified Nutritional Deficiency

The use of folic acid is contraindicated in patients with undiagnosed anemia. Folic acid in dosages above 1 mg/day can obscure the diagnosis of pernicious anemia by alleviating the hematologic abnormalities while allowing the progression of neurologic complications. In addition, folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient.

Major

Vitamin D analogs (applies to DermacinRx ​ FoliPlus D) arrhythmia

Major Potential Hazard, High plausibility. Applicable conditions: Arrhythmias

Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.

Major

Vitamin D analogs (applies to DermacinRx ​ FoliPlus D) electrolyte imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Phosphate Imbalance

Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.

Major

Vitamin D analogs (applies to DermacinRx ​ FoliPlus D) hypercalcemia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Malabsorption Syndrome

Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.

Major

Vitamin D analogs (applies to DermacinRx ​ FoliPlus D) renal dysfunction

Major Potential Hazard, High plausibility.

Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.

Moderate

Vitamin D analogs (applies to DermacinRx ​ FoliPlus D) hepatobiliary dysfunction

Moderate Potential Hazard, High plausibility. Applicable conditions: Liver Disease, Biliary Obstruction

Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.

Switch to professional interaction data

DermacinRx ​ FoliPlus D drug interactions

There are 115 drug interactions with DermacinRx ​ FoliPlus D (cholecalciferol / folic acid).

DermacinRx ​ FoliPlus D alcohol/food interactions

There are 2 alcohol/food interactions with DermacinRx ​ FoliPlus D (cholecalciferol / folic acid).


Report options

Loading...
QR code containing a link to this page

More about DermacinRx ​ FoliPlus D (cholecalciferol / folic acid)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.